Doxorubicin

Form: Injection

Strength: 10 mg/5 mL, 50 mg/25 mL, 200 mg/100 mL (in vials)

Reference Brands: Adriamycin® (EU & US)

Category: Oncology Cancer Care

Doxorubicin is a potent chemotherapy drug used to treat a wide range of cancers, including breast cancer, leukemia, and lymphomas. As an anthracycline, it works by inhibiting DNA replication in cancer cells, leading to cell death. Available in 10 mg/5 mL, 50 mg/25 mL, and 200 mg/100 mL vial strengths, Doxorubicin is marketed as Adriamycin® in both the US and EU. With its significant role in cancer treatment, it offers substantial B2B opportunities for pharmaceutical companies targeting oncology treatments in these regions.